Idorsia and Viatris update their collaboration for selatogrel and cenerimod
Portfolio Pulse from
Idorsia and Viatris have updated their collaboration terms for the development and commercialization of selatogrel and cenerimod. Idorsia's development cost contribution is reduced by $100 million, while Viatris' potential payments to Idorsia are reduced by $250 million.
February 26, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Viatris has updated its collaboration with Idorsia, reducing potential regulatory and sales milestone payments by $250 million. This may impact Viatris' financial obligations and future earnings.
The reduction in potential payments by $250 million could positively impact Viatris' cash flow and financial obligations. However, the long-term impact on earnings will depend on the success of selatogrel and cenerimod.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80